What is the target price for 23andMe stock?
Apr 03, 2022 · 23andMe trades on the NASDAQ under the ticker symbol "ME." Who are 23andMe's major shareholders? 23andMe's stock is owned by …
What is 23andMe and how does it work?
ME | Complete 23andMe Holding Co. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
How does 23andMe's insider ownership look like?
Apr 18, 2022 · Genetic testing company 23andMe Holding Co. (NASDAQ: ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction …
Is 23andMe making a comeback?
23andMe Holding Co. Class A Common Stock (ME) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
How do I buy 23andMe stock?
How to buy shares in 23andMe HoldingCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
Is 23andMe public?
It's been far from a smooth ride since 23andMe's stock market debut. The Silicon Valley-based genetics testing firm went public in June via a merger with a special acquisition company led by U.K. billionaire Richard Branson in a deal that raised nearly $600 million and boosted 23andMe's value to $3.5 billion.Dec 1, 2021
What will 23andMe stock price be?
3.0600Performance OutlookPrevious Close3.0600Ask3.2400 x 3200Day's Range2.9999 - 3.260052 Week Range2.9999 - 13.6800Volume2,376,6133 more rows
Why is 23andMe stock so low?
23andMe's stock has tumbled as a result of its weak revenue growth. New income from drug development collaborations could increase over time. It's difficult to value an enterprise that's in the midst of a pivot.Feb 16, 2022
Who bought 23andMe?
VG Acquisition Corp.23andMe going public at $3.5B via merger with Branson's blank check company. 23andMe is merging with VG Acquisition Corp., a special purpose acquisition company founded by billionaire Richard Branson, to go public. The deal values the consumer genetic testing company at $3.5 billion, including debt.
Who funded 23andMe?
Linda Avey, Paul Cusenza and Anne Wojcicki founded 23andMe in 2006 to offer genetic testing and interpretation to individuals. In 2007, Google invested $3.9 million in the company, along with Genentech, New Enterprise Associates, and Mohr Davidow Ventures.
Can you invest in 23andMe?
Unlike traditional IPOs, 23andMe is going public through a special purpose acquisition company (SPAC).Feb 1, 2022
Is ME stock good to buy?
23andMe Holding Co. finds support from accumulated volume at $3.37 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock has average movements during the day and with good trading volume, the risk is considered to be medium.
When did 23andMe go public?
According to a 23andMe news release, “The combined company is called 23andMe Holding Co. and will be traded on The Nasdaq Global Select Market (“NASDAQ”) beginning on June 17, 2021, under the new ticker symbol 'ME' for its Class A Common shares and 'MEUSW' for its public warrants.”Aug 4, 2021
Is Anne Wojcicki a billionaire?
Wojcicki became an on-paper billionaire earlier this year, when her genetics testing company went public in a SPAC that valued 23andMe at $3.5 billion. But for the first nine years of her company's life, Wojcicki was also married to Sergey Brin, the cofounder of Google and now the world's sixth-wealthiest man.Dec 2, 2021
Is 23andMe being shorted?
23andMe currently has a short interest ratio of 8.0.
What is 23andMe doing with DNA?
Since late 2007, 23andMe has been known for offering cut-rate genetic testing. Spit in a vial, send it in, and the company will look at thousands of regions in your DNA that are known to vary from human to human—and which are responsible for some of our traits.Nov 27, 2013
Is 23andMe a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating and 1...
When is 23andMe's next earnings date?
23andMe is scheduled to release its next quarterly earnings announcement on Thursday, May 12th 2022. View our earnings forecast for 23andMe .
How were 23andMe's earnings last quarter?
23andMe Holding Co. (NASDAQ:ME) announced its quarterly earnings data on Thursday, February, 10th. The company reported ($0.21) earnings per share...
What guidance has 23andMe issued on next quarter's earnings?
23andMe issued an update on its FY 2022 earnings guidance on Thursday, February, 24th. The company provided earnings per share guidance of for the...
What price target have analysts set for ME?
2 analysts have issued 12 month price objectives for 23andMe's shares. Their forecasts range from 6.00 to 11.00. On average, they expect 23andMe's...
Who are 23andMe's key executives?
23andMe's management team includes the following people: Ms. Anne Wojcicki , Co-Founder, CEO, Pres & Director Mr. Steven J. Schoch , CFO & Treas...
Who are some of 23andMe's key competitors?
Some companies that are related to 23andMe include Arena Pharmaceuticals (ARNA) , Legend Biotech (LEGN) , Intra-Cellular Therapies (ITCI) , Per...
What is 23andMe's stock symbol?
23andMe trades on the NASDAQ under the ticker symbol "ME."
Who are 23andMe's major shareholders?
23andMe's stock is owned by a number of institutional and retail investors. Top institutional investors include Revelation Capital Management LLC (...
Is 23andMe a buy right now?
What stocks does MarketBeat like better than 23andMe?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" 23andMe stock.#N#View analyst ratings for 23andMe or view top-rated stocks.
When is 23andMe's next earnings date?
Wall Street analysts have given 23andMe a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 23andMe wasn't one of them.
How were 23andMe's earnings last quarter?
23andMe is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.#N#View our earnings forecast for 23andMe.
What guidance has 23andMe issued on next quarter's earnings?
23andMe Holding Co. (NASDAQ:ME) released its earnings results on Friday, August, 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.32. The business had revenue of $59.24 million for the quarter.#N#View 23andMe's earnings history.
What price target have analysts set for ME?
23andMe issued an update on its FY 2022 earnings guidance on Friday, September, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250 million-$260 million.
Who are some of 23andMe's key competitors?
2 equities research analysts have issued 12-month price targets for 23andMe's shares. Their forecasts range from 12.00 to 13.00. On average, they anticipate 23andMe's stock price to reach 12.50 in the next year.
Recently Viewed Tickers
Some companies that are related to 23andMe include Zai Lab (ZLAB), CureVac (CVAC), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr.
23andMe Holding Co
Visit a quote page and your recently viewed tickers will be displayed here.
Who is the CEO of 23andme?
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to consumer genetic testing through its Personal Genome Service, and also food and drug administration authorizations for genetic health risk reports.
Who is VG Acquisition Corp?
Jun.17 -- 23andMe Inc. CEO Anne Wojcicki discusses the DNA-testing company's NASDAQ trading debut, a collaboration on drug development with GlaxoSmithKline Plc, and the choice to go public through a mer...
What is Weisslaw LLP investigating?
NEW YORK, June 10, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group ("VGAC" or the "Company") today announced that its shareholders...
Is 23andme a public company?
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of VG Acquisition Corp. ("VGAC" or the "Com...
What is 23andme test?
23andMe jumps on stock market debut, as privacy concerns about genetic testing abound. The company is the latest to go public via a SPAC deal. 23andMe, the direct-to-consumer genetic testing company headquartered in Sunnyvale, California, popped on its stock market debut Thursday. Other stocks mentioned: VGAC.
Who is Zhiyuan Sun?
23andMe is known for its namesake health and ancestry testing services. After purchasing and receiving its test kit, consumers ship a saliva sample to a laboratory for analysis. The results include a complete breakdown of the user's genetic background. Customers can also use the data to locate close relatives on the 23andMe platform.
Does 23andme have genetic testing?
Zhiyuan Sun is a statistician with a knack for analyzing clinical trials and company financials. Investing in healthcare and cannabis is his passion, as well as looking out for new, actionable stock investment ideas in these sectors. Fool since April 2020.
